National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$63.25
add to cart

Rights & Permissions

topleft topright

Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary (2005)
Board on Science, Technology, and Economic Policy (STEP)
National Cancer Policy Board (NCPB)

Citation Manager

. "Appendix P Natural History of Colorectal Adenomas and Cancer--T. R. Levin, M.D.." Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
284
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary

McArdle CS, McMillan DC, Hole DJ. 2003. Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg. 90(6):711–5.

Morson BC. 1984. The evolution of colorectal carcinoma. Clin Radiol. 35(6):425–31.


Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. 2003. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst. 95(8):622–5.


Rabeneck L, Souchek J, El-Serag HB. 2003. Survival of colorectal cancer patients hospitalized in the Veterans Affairs Health Care System. Am J Gastroenterol. 98(5):1186–92.


Schoen RE, Pinsky PF, Weissfeld JL, Bresalier RS, Church T, Prorok P, Gohagan JK. 2003. Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA. 290(1):41–8.

Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. 1992. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 326(10):653–7.

Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M, Summerhayes IC. 1996. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 335(23):1727–32.

Stryker SJ, Wolff BG, Gulp CE, Libbe SD, Ilstrup DM, MacCarty RL. 1987. Natural history of untreated colonic polyps. Gastroenterology. 93(5):1009–13.


Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. 1999. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol. 34(4):414–20.


Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR. 2001. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 344(16):1196–206.

Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ. 1997. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 112(2):594–642.

Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, et al. 1993. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 329(27):1977–81.

Page
284
Front Matter (R1-R8)
Workshop Summary (1-30)
References (31-34)
Appendix A Workshop Agenda: Economic Models of Colorectal Cancer Screening in Average-Risk Adults (35-36)
Appendix B Workshop Participants (37-38)
Appendix C Workshop Speaker and Staff Biographies (39-44)
Appendix D Overview of Harvard Model--Karen M. Kuntz, ScD. (45-60)
Appendix E Description of the Laudabaum Colorectal Cancer Screening Model--Uri Ladabaum, M.D., M.S. (61-72)
Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema (73-83)
Appendix G The Vanderbilt Colorectal Cancer Model--R.M. Ness, R.W. Klein, R.S. Dittus (84-104)
Appendix H Overview of the Vijan Colorectal Cancer Screening Model--Sandeep Vijan, M.D., M.S. (105-117)
Appendix I Cost-Effectiveness Analyses of Colorectal Cancer Screening: Results from a Pre-conference Modeling Exercise--Michael Pignone, M.D., (118-153)
Appendix J Recent Findings on Test Performance--Brian P. Mulhall, M.D., M.P.H. (154-188)
Appendix K Cost Issues in Cost Effectiveness Modeling of Colorectal Cancer Screening--Martin L. Brown, Ph.D. (189-207)
Appendix L Current Evidence on Compliance --Sally W. Vernon, M.A., Ph.D. (208-219)
Appendix M Recent Trends in Follow-up Surveillance in Medicare Beneficiaries--Todd Anderson, M.S. (220-231)
Appendix N Preliminary Results from CDC (232-240)
Appendix O Colorectal Cancer Surveillance Testing After Polypectomy--Deborah Schrag, M.D., M.P.H. (241-262)
Appendix P Natural History of Colorectal Adenomas and Cancer--T. R. Levin, M.D. (263-284)
Appendix Q CISNET—Cancer Intervention and Surveillance--Eric J. (Rocky) Feuer, Ph.D. (285-300)